STAAR Surgical Q1 Earnings Surge 119% YoY

STAAR Surgical posted Q1 2026 GAAP EPS $0.10, net sales $93.5 million, up 119.6% YoY, beating estimates.
After shareholders rejected Alcon’s $30.75 per share buyout, STAAR installed interim Co‑CEOs Warren Foust and Deborah Andrews, adopting a standalone strategy.
Operating income swung to $8.0 million from a $57.4 million loss year‑over‑year, and adjusted EBITDA turned to $24.4 million profit.
China sales hit $47.4 million on the EVO+ ICL launch, while U.S. sales rose 22% to over $6 million despite a 7% drop.